CNBX Pharmaceuticals Inc., a clinical-stage biotechnology company based in Bethesda, Maryland, reported no revenue for the fiscal year ending August 31, 2025, a significant decline from $130,074 in the previous year. The company has not generated substantial revenue since transitioning from its previous operations in oil and gas to focus on cannabinoid-based therapies for cancer treatment. Total operating expenses for the year were $271,691, down from $713,214 in 2024, primarily due to reduced general and administrative costs and a decrease in research and development expenditures. The net loss for the year was $313,976, compared to a net loss of $695,198 in the prior year.
The company’s financial position remains precarious, with cash reserves decreasing to $15,111 as of August 31, 2025, from $26,416 a year earlier. CNBX has relied on financing through convertible loans, raising $160,000 in the latest fiscal year, compared to $27,512 in 2024. The company continues to face substantial doubt about its ability to continue as a going concern, as highlighted by its independent auditors. The ongoing need for additional capital to fund operations and development activities is critical, and the company has not established any arrangements for future financing.
Strategically, CNBX Pharmaceuticals is focused on advancing its lead product candidates, Cannabics SR and RCC-33, which are intended for the treatment of cancer and cancer-related cachexia. The company plans to initiate Phase I/II clinical trials for these candidates in 2026, contingent upon securing adequate funding. The company has also made organizational changes, including the appointment of new advisors with expertise in oncology, to enhance its research and development capabilities.
Operationally, CNBX has not reported significant user statistics or customer counts, as it is still in the early stages of product development. The company has a limited workforce, with only one employee as of August 31, 2025, and has not engaged in any manufacturing or distribution activities. The company’s market share remains negligible, and it has not yet established a sales or marketing infrastructure, relying instead on potential licensing agreements with larger pharmaceutical companies for commercialization.
Looking ahead, CNBX Pharmaceuticals acknowledges the challenges it faces in securing funding and achieving regulatory approvals for its product candidates. The company’s future success will depend on its ability to navigate the complex landscape of biotechnology development, including compliance with regulatory requirements and the successful execution of its clinical trials. The management remains optimistic about the potential of cannabinoid-based therapies but recognizes the inherent risks and uncertainties associated with the biotechnology sector.
About CNBX Pharmaceuticals Inc.
CNBX Pharmaceuticals Inc. is a clinical-stage biotech company developing cannabinoid-based therapies for cancer treatment, focusing on products like Cannabics SR for cancer cachexia and RCC-33 for colorectal cancer. It advances drug discovery, IP protection, and regulatory pathways, aiming for FDA approval and strategic licensing. The company emphasizes innovative formulations, preclinical and clinical trials, and partnerships, targeting unmet medical needs in oncology with a competitive edge in cannabinoid research.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.